Friday’s Must-Watch Stock: Chelsea Therapeutics International Ltd.

Chelsea Therapeutics' (NASDAQ: CHTP  ) drug Northera has its Prescription Drug User Fee Act, or PDUFA, date on Friday. The drug treats dizziness and fainting in people with diseases like Parkinson's.

The FDA remains somewhat skeptical about the durability of efficacy of the drug, according to briefing documents, even though an advisory committee voted 16-to-1 in favor of approval. The company has, however, received a similarly positive vote before, and still came up against FDA rejection, so an advisory committee vote does not mean certain approval.

The drug has been sold for decades in Japan, but in this video from Wednesday's Market Checkup, Motley Fool health-care analyst David Williamson says that he's not sure ultimately how the FDA will decide on this one. It could go either way, and is a situation he's going to be monitoring very closely.

So what's the best way for investors to play the biotech space?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 12, 2014, at 10:56 PM, snowday97 wrote:

    " received a similarly positive vote before, and still came up against FDA rejection,"

    Yes, but it's different, last time it was only 7:4 (63% approval from the advisory panel )

    This time, advisory panel approved 16:1 (94%) approval.

    This is the deal, and this is the point. So most likely, it will get approval.

Add your comment.

DocumentId: 2837357, ~/Articles/ArticleHandler.aspx, 4/21/2014 11:07:43 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement